🔎 Trials Near Me

Utama › Obesiti › Arizona › Phoenix

Kajian klinikal Obesiti di Phoenix, AZ

22 kajian untuk Obesiti sedang mencari peserta di lokasi dalam dan sekitar Phoenix (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Early Tracking of Childhood Health Determinants (ETCHED) Study

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • NIDDK, Phoenix, Phoenix
1 Day – 99 Years · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03481829

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Mengambil pesertaFasa 3
  • RIO Clinical Trials - Phoenix, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Mengambil pesertaFasa 3
  • Research Site, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Mengambil pesertaFasa 3
  • Synexus Clinical Research US, Inc., Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Mengambil pesertaFasa 3
  • Elite Clinical Studies, LLC, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07353931

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Mengambil pesertaSukarelawan sihat dialu-alukan
  • NIDDK, Phoenix, Phoenix
Umur 18 hingga 99 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06223555

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Mengambil pesertaFasa 3
  • AURORA-1 Clinical Site, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Mengambil pesertaFasa 3
  • AURORA-2 Clinical Site, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Mengambil pesertaFasa 3
  • HonorHealth, Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
Umur 18 hingga 99 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Mengambil pesertaFasa 2
  • Helios Clinical Research - Phoenix, Phoenix
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
  • ACCOMPLISH-2 Research Site, Phoenix
Umur 18 hingga 79 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07654374

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Mengambil pesertaFasa 2
  • Synexus Clinical Research US, Inc., Phoenix
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Mengambil pesertaFasa 3
  • Kailera Clinical Site, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284901

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Mengambil pesertaFasa 3
  • Kailera Clinical Site, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07284979

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Mengambil pesertaSukarelawan sihat dialu-alukan
  • NIDDK, Phoenix, Phoenix
Umur 18 hingga 60 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05545306

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

Mengambil pesertaKajian pemerhatian
  • Exponent Phoenix, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07776678

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Mengambil pesertaFasa 3
  • Honor Health, Phoenix
  • Arizona Research Center, Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Mengambil pesertaFasa 3
  • ACCOMPLISH-1 Research Site, Phoenix
Umur 18 hingga 79 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07654361

Fibrosis Lessens After Metabolic Surgery

Mengambil pesertaFasa 4Sukarelawan sihat dialu-alukan
  • Banner Health Center, Phoenix
Umur 18 hingga 75 · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06374875

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Mengambil pesertaFasa 3
  • Arizona Research Center, Inc., Phoenix
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2026 · NCT07481630

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Mengambil pesertaFasa 3
  • The University of Arizona College of Medicine- Phoenix, Phoenix
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Nov 2025 · NCT06499857

Kajian Obesiti di bandar lain

Kajian lain di Phoenix

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.